REMEDENT, INC. | 2013 | FY | 3

As of March 31, 2013 and March 31, 2012, the Company had warrants to purchase the Company’s common stock outstanding that were not granted under shareholder approved equity compensation plans as follows:
 
 
Outstanding
Warrants
 
Weighted
Average
Exercise
Price
 
Warrants and options outstanding, March 31, 2011
 
 
7,794,627
 
$
1.50
 
Expired
 
 
(4,056,248)
 
 
 
 
Warrants outstanding March 31, 2012 and March 31, 2013
 
 
3,738,379
 
 
1.50
 
Warrants exercisable March 31, 2012 and March 31, 2013
 
 
3,738,379
 
$
1.50
 
Exercise price range
 
$
1.00 to $1.65
 
 
 
 
Weighted average remaining life
 
 
.40 Years
 
 
 
 

us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock